The Sjogren’s syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage pipeline products will significantly revolutionize the Sjogren’s syndrome market dynamics.
DelveInsight’s “Sjogren’s syndrome Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Sjogren’s syndrome, historical and forecasted epidemiology as well as the Sjogren’s syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Sjogren’s syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Sjogren’s syndrome Market Insights
Some of the key facts of the Sjogren’s syndrome Market Report:
-
The Sjogren’s syndrome market size was valued ~USD 1,900 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).
-
In August 2025, Novartis was seeking approval for its Sjögren’s disease therapy after positive results from two Phase III trials. The NEPTUNUS-1 (NCT05350072) and NEPTUNUS-2 (NCT05349214) studies evaluating ianalumab achieved their primary goal of reducing disease activity, as measured by the EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) compared to placebo. The trials included 749 patients, with NEPTUNUS-1 assessing monthly intravenous ianalumab and NEPTUNUS-2 evaluating the safety and efficacy of subcutaneous ianalumab administered either monthly or every three months.
-
In March 2025, Drawing on results from the Phase II DAHLIAS (NCT04968912) trial, the FDA has awarded Fast Track designation (FTD) to nipocalimab for the treatment of moderate-to-severe Sjögren’s disease. This marks the first Fast Track granted to an FcRn blocker for this condition and is expected to accelerate the development of the investigational therapy, which, if approved, would become the first FcRn blocker indicated for this autoantibody-driven disease.
-
In March 2025, Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to its investigational therapy, nipocalimab, for treating adults with moderate-to-severe Sjögren's disease (SjD). This follows the Breakthrough Therapy designation (BTD) received for the same therapy late last year. Presently, there are no advanced treatments approved specifically for this condition.
-
In November 2024, Johnson & Johnson (J&J) has announced encouraging findings from the Phase II DAHLIAS trial evaluating nipocalimab, a neonatal Fc receptor (FcRn) blocker, for the treatment of moderate-to-severe Sjögren’s disease (SjD). This placebo-controlled, multicenter, double-blind study examined the efficacy of nipocalimab in adults with primary Sjögren’s syndrome.
-
In June 2024, Johnson & Johnson reported results from the Phase II DAHLIAS dose-ranging study, where its monoclonal antibody nipocalimab showed significant improvements in Sjögren's disease (SjD) activity in patients. DAHLIAS is a randomized, multicenter, placebo-controlled, double-blind trial that assessed the effects of nipocalimab in adults with primary SjD, a chronic and debilitating autoimmune disorder.
-
Novartis and Amgen are leading companies in the Sjogren’s syndrome market, with their drugs CFZ533 (iscalimab) and VIB4920 (dazodalibep) projected to achieve the highest revenue across the 7MM by 2034.
-
Across the 7MM, approximately 1.5 million diagnosed prevalent cases of Sjogren’s syndrome were recorded in 2023, with this number anticipated to grow over the forecast period (2024–2034).
-
In the US, antigen-specific cases were most commonly associated with auto-antibodies positivity, followed by anti-Ro/SSA positivity and anti-La/SSB positivity in 2023.
-
In 2023, the United States recorded the highest number of treated cases of Sjogren’s syndrome, while Japan reported the lowest, with approximately 54,000 treated cases. These figures are projected to increase by 2034.
-
Within the EU4 and the UK, Sjogren’s syndrome predominantly affected females, with the United Kingdom reporting the highest number of gender-specific cases in 2023.
-
Key Sjogren’s syndrome Companies: Rise Therapeutics, Bristol-Myers Squibb, Resolve Therapeutics, Novartis, Horizon Therapeutics, Dompe Farmaceutici, Horizon Therapeutics (Amgen), Sylentis, OSE Immunotherapeutics, Servier, Johnson & Johnson, and others
-
Key Sjogren’s syndrome Therapies: R-2487, BMS-986325, RSLV-132, CFZ533, VIB4920, VAY736, Dazodalibep (VIB4920), OXERVATE (cenegermin), Tivanisiran (SYL1001), Lusvertikimab (formerly OSE-127), Nipocalimab, and others
Sjogren’s syndrome Overview
The two most prevalent symptoms of Sjogren's syndrome, an immune system illness, are dry eyes and a dry mouth. The syndrome frequently coexists with other immune system diseases like lupus and rheumatoid arthritis. Sjogren's syndrome often affects your mucous membranes and moisture-secreting glands in your mouth and eyes first, which causes less saliva and tears to be produced.
Although Sjogren's syndrome can strike at any age, most cases of the condition are detected in patients over the age of 40. In women, the illness is far more prevalent. The goal of Sjogren's syndrome treatment is to reduce symptoms.
Get a Free sample for the Sjogren’s syndrome Market Report:
https://www.delveinsight.com/report-store/sjogrens-syndrome-market-size
Sjogren’s syndrome Epidemiology Segmentation:
The Sjogren’s syndrome market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
-
Total Prevalence of Sjogren’s syndrome
-
Prevalent Cases of Sjogren’s syndrome by severity
-
Gender-specific Prevalence of Sjogren’s syndrome
-
Diagnosed Cases of Episodic and Chronic Sjogren’s syndrome
Download the report to understand which factors are driving Sjogren’s syndrome epidemiology trends @ Sjogren’s syndrome Epidemiological Insights
Sjogren’s syndrome Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Sjogren’s syndrome market or expected to get launched during the study period. The analysis covers Sjogren’s syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Sjogren’s syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Sjogren’s syndrome Therapies and Key Companies
-
R-2487: Rise Therapeutics
-
BMS-986325: Bristol-Myers Squibb
-
RSLV-132: Resolve Therapeutics
-
CFZ533: Novartis
-
VIB4920: Horizon Therapeutics
-
VAY736: Novartis
-
Dazodalibep (VIB4920): Horizon Therapeutics (Amgen)
-
OXERVATE (cenegermin): Dompe Farmaceutici
-
Tivanisiran (SYL1001): Sylentis
-
Lusvertikimab (formerly OSE-127): OSE Immunotherapeutics/Servier
-
Nipocalimab: Johnson & Johnson
To know more about Sjogren’s syndrome treatment, visit @ Sjogren’s syndrome Medications
Sjogren’s syndrome Market Drivers
-
Increasing Prevalence
-
Advancements in Diagnostics
-
Sjogren’s syndrome Pipeline Therapies
-
Supportive Regulatory Environment
-
Growing Awareness
Sjogren’s syndrome Market Barriers
-
Limited Treatment Options
-
High Treatment Costs
-
Side Effects of Therapies
-
Delayed Diagnosis
-
Lack of Awareness
Scope of the Sjogren’s syndrome Market Report
-
Study Period: 2020–2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Sjogren’s syndrome Companies: Rise Therapeutics, Bristol-Myers Squibb, Resolve Therapeutics, Novartis, Horizon Therapeutics, Dompe Farmaceutici, Horizon Therapeutics (Amgen), Sylentis, OSE Immunotherapeutics, Servier, Johnson & Johnson, and others
-
Key Sjogren’s syndrome Therapies: R-2487, BMS-986325, RSLV-132, CFZ533, VIB4920, VAY736, Dazodalibep (VIB4920), OXERVATE (cenegermin), Tivanisiran (SYL1001), Lusvertikimab (formerly OSE-127), Nipocalimab, and others
-
Sjogren’s syndrome Therapeutic Assessment: Sjogren’s syndrome current marketed and Sjogren’s syndrome emerging therapies
-
Sjogren’s syndrome Market Dynamics: Sjogren’s syndrome market drivers and Sjogren’s syndrome market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Sjogren’s syndrome Unmet Needs, KOL’s views, Analyst’s views, Sjogren’s syndrome Market Access and Reimbursement
Discover more about therapies set to grab major Sjogren’s syndrome market share @ Sjogren’s syndrome Treatment Landscape
Table of Contents
1. Sjogren’s syndrome Market Report Introduction
2. Executive Summary for Sjogren’s syndrome
3. SWOT analysis of Sjogren’s syndrome
4. Sjogren’s syndrome Patient Share (%) Overview at a Glance
5. Sjogren’s syndrome Market Overview at a Glance
6. Sjogren’s syndrome Disease Background and Overview
7. Sjogren’s syndrome Epidemiology and Patient Population
8. Country-Specific Patient Population of Sjogren’s syndrome
9. Sjogren’s syndrome Current Treatment and Medical Practices
10. Sjogren’s syndrome Unmet Needs
11. Sjogren’s syndrome Emerging Therapies
12. Sjogren’s syndrome Market Outlook
13. Country-Wise Sjogren’s syndrome Market Analysis (2020–2034)
14. Sjogren’s syndrome Market Access and Reimbursement of Therapies
15. Sjogren’s syndrome Market drivers
16. Sjogren’s syndrome Market barriers
17. Sjogren’s syndrome Appendix
18. Sjogren’s syndrome Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
-
Key Sjogren’s syndrome Companies: Rise Therapeutics, Bristol-Myers Squibb, Resolve Therapeutics, Novartis, Horizon Therapeutics, Dompe Farmaceutici, Horizon Therapeutics (Amgen), Sylentis, OSE Immunotherapeutics, Servier, Johnson & Johnson, and others
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
